XML 42 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Accounting Policies [Line Items]        
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net $ (14,640) [1] $ 9,071 $ (1,577) [1] $ 3,715
Foreign Currency Transaction Gain (Loss), Realized 5,131 [2] (12,434) 11,691 [2] (2,071)
Other Nonoperating Gains (Losses) 68 (288) 631 733
Other (expense) income, net (9,441) (3,651) 10,745 2,377
Realized gain (loss) on derivatives not designated as hedging instruments $ 4,434 [1] $ 349 $ 5,183 $ 838
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 60   $ 60  
Weighted average shares outstanding — diluted 24,834,409 26,216,216 25,841,781 27,143,619
Weighted average shares issuable upon exercise/vesting of outstanding share options/PSUs/RSUs/warrants (1)(2) [3],[4] 0 0 851,362 711,196
Share-Based Payment Arrangement, Expense     $ 562  
Stock Repurchased and Retired During Period, Shares 714,667      
Purchase of ordinary shares     $ 56,934 $ 100,729
Net Income (Loss) Per Share Attributable to Cimpress plc [Line Items]        
Weighted average shares outstanding — basic 24,834,409 26,216,216 24,990,419 26,432,423
Weighted average shares issuable upon exercise/vesting of outstanding share options/PSUs/RSUs/warrants (1)(2) [3],[4] 0 0 851,362 711,196
Weighted average shares outstanding — diluted 24,834,409 26,216,216 25,841,781 27,143,619
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount [3],[4] 2,083,040 955,594 312,874 127,229
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,055,377   1,055,377  
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 1,055,377 309,000 196,438 184,608
Foreign Exchange Forward [Member]        
Accounting Policies [Line Items]        
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net $ (14,640) $ 9,071 $ (1,577) $ 3,715
[1] Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments. For contracts not designated as hedging instruments, we realized gains of $4,434 and $5,183 for the three and nine months ended March 31, 2025, respectively, and losses of $349 and $838 for the three and nine months ended March 31, 2024, respectively. Refer to Note 4 for additional details relating to our derivative contracts.
[2] Currency-related gains (losses), net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility. In addition, during the three and nine months ended March 31, 2024, we recognized gains of $1,748 and $1,454, respectively, on a cross-currency swap designated as a cash flow hedge which hedges the remeasurement of an intercompany loan. We did not hold any cross-currency swap contracts that were designated as cash flow hedges during the three and nine months ended March 31, 2025. Refer to Note 4 for additional details regarding our cash flow hedges.
[3] In the periods in which a net loss is recognized, the impact of share options, PSUs, RSUs and warrants is excluded from shares used in computed diluted net loss per share as it is anti-dilutive.
[4] On May 1, 2020, we entered into a financing arrangement which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60 that have a potentially dilutive impact on our weighted average shares outstanding. For the three months ended March 31, 2025, the average share price was below the strike price for the quarter; therefore, the total outstanding warrants were considered anti-dilutive. The weighted average anti-dilutive effect of the warrants for the three months ended March 31, 2025 and 2024 was 1,055,377 and 309,000 (anti-dilutive due to our net loss position), respectively, and the weighted average dilutive effect of the warrants for the nine months ended March 31, 2025 and 2024 was 196,438 and 184,608, respectively.